Composition for preventing or treating muscular diseases, or for improving muscular functions, containing gagnlioside

Patent metadata

Field	Value
Publication number	US-2021353659-A1
Application number	US-201917271031-A
Country	US
Kind code	A1
Filing date	Aug 24, 2018
Priority date	Aug 24, 2018
Publication date	Nov 18, 2021
Grant date	—

Abstract

The present invention relates to compositions for preventing or treating a muscle disease or improving muscle functions including a ganglioside. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a muscle disease, a food composition for preventing or ameliorating a muscle disease, and a cosmetic composition for preventing or ameliorating a muscle disease. Each of the compositions includes a ganglioside that increases the expression of proteins associated with muscle protein synthesis in muscle cells and an increase in muscle mass and inhibits the expression of enzymes involved in muscle protein degradation at the mRNA level.

First claim

We claim:

1 - 19 . (canceled)

20 . A method for preventing or treating a muscle disease in a subject in need thereof, administration a composition comprising a ganglioside as an active ingredient.

21 . The method according to claim 20 , wherein the ganglioside is represented by Formula 1:

wherein X is GalNAc or Y-Gal-GalNAc, Y is [SA] m , Gal is galactose, Glc is glucose, Cer is ceramide, GalNAc is N-acetylgalactosamine, SA is sialic acid, n is an integer from 1 to 3, and m is an integer from 0 to 2.

22 . The method according to claim 21 , wherein the ganglioside of Formula 1 is selected from ganglioside GM3, ganglioside GM1, ganglioside GD1a, ganglioside GT1b, and ganglioside GQ1b.

23 . The method according to claim 22 , wherein the ganglioside GM3 is represented by Formula 2, wherein the ganglioside GM3 is represented by Formula 2, wherein the ganglioside GM1 is represented by Formula 3, wherein the ganglioside GD1a is represented by Formula 4, wherein the ganglioside GT1b is represented by Formula 5, wherein the ganglioside GQ1b is represented by Formula 6,

24 . The method according to claim 20 , wherein the ganglioside is extracted, concentrated or separated from antler, sweet potato, colostrum, milk or a mixture thereof.

25 . The method according to claim 20 , wherein the muscle disease is caused by muscle dysfunction, muscle wasting or muscle degeneration.

26 . The method according to claim 20 , wherein the muscle disease is selected from atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia gravis, cachexia, age-related sarcopenia, and combinations thereof.

27 . The method according to claim 20 , wherein the composition is a pharmaceutical composition, a food composition or a cosmetic composition.

Assignees

• Univ Yonsei Iacf

Inventors

• Hwang Jae Kwan
• Su Seung Tae
• Kim Jong Wook
• Kim Chang-Hee
• Yoo Ji Hee

Classifications

• A23L33/125

  containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21) · CPC title

• A23L33/12

  Fatty acids or derivatives thereof · CPC title

• A61K31/7032 Primary

  attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides · CPC title

• A61P21/06

  Anabolic agents (androgens A61P5/26) · CPC title

• A61K31/739 Primary

  Lipopolysaccharides · CPC title